1
|
Gallamini A, Rambaldi A, Patti C, Romano A, Viviani S, Bolis S, Oppi S, Trentin L, Cantonetti M, Sorasio R, Gavarotti P, Gottardi D, Schiavotto C, Battistini R, Gini G, Ferreri A, Pavoni C, Bergesio F, Ficola U, Guerra L, Chauvie S. BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.19_2879] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - A Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - C Patti
- Ospedali Riuniti di Palermo Hematology Palermo Italy
| | - A Romano
- Policlinico Universitario A. Ferrarotto Hematology Catania Italy
| | - S Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - S Bolis
- Ospedale S. Gerardo Hematology Monza Italy
| | - S Oppi
- Ospedale Antonio Businco Hematology Cagliari Italy
| | - L Trentin
- Azienda Ospedaliera di Padova Hematology Padova Italy
| | | | - R Sorasio
- Ospedale S. Croce e Carle Hematology Cuneo Italy
| | - P Gavarotti
- Ospedale S. Giovanni Battista Hematology ‐ University Torino Italy
| | - D Gottardi
- Ospedale Mauriziano Hematology Torino Italy
| | | | - R Battistini
- Ospedale S. Camillo Forlanini Hematology Roma Italy
| | - G Gini
- Ospedali Riuniti di Ancona Hematology Ancona Italy
| | | | - C Pavoni
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - F Bergesio
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - U Ficola
- Ospedale La Maddalena Nuclear Medicine Palermo Italy
| | - L Guerra
- Ospedale S. Gerardo Nuclear Medicine Monza Italy
| | - S Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| |
Collapse
|
2
|
Gallamini A, Walewski J, Rambaldi A, Viviani S, Sureda A, André M, Rossi C, Moccia A, Zucca E, Rossi D, Filippi A, Meignan M, Chauvie S, Zaucha JM. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.158_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - J. Walewski
- Marii Skłodowskiej‐Curie Institute Onco‐Hematology Warsaw Poland
| | - A. Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - S. Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - A. Sureda
- Institut Català d'Oncologia Hematology Barcelona Spain
| | - M. André
- Cliniques universitaires Saint‐Luc ‐ UC Louvain Hematology Louvain Belgium
| | - C. Rossi
- CHU Bocage Hematology Dijon France
| | - A. Moccia
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - E. Zucca
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - D. Rossi
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - A. Filippi
- Policlinico S. Matteo IRCCS Radiation Oncology Pavia Italy
| | - M. Meignan
- Henry Mondor Hospital LYSA Imaging Paris France
| | - S. Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - J. M. Zaucha
- Medical University of Gdansk Hematology Gdansk Poland
| |
Collapse
|
3
|
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Bertolotti L, Pavoni C, Parvis G, Zanotti R, Gavarotti P, Cimminiello M, Schiavotto C, Viero P, Avigdor A, Tarella C, Rambaldi A. CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Gallamini
- Research & Clinical Innovation; Antoine Lacassagne Cancer Centre; Nice France
| | - A. Rossi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - C. Patti
- Hematology; V. Cervello Hospital; Palermo Italy
| | - M. Picardi
- Hematology; Policlinico Federico II; Naples Italy
| | - A. Romano
- Hematology; Policlinico Vittorio Emanuele Hospital; Catania Italy
| | - M. Cantonetti
- Hematology; Policlinico Hospital Tor Vergata; Rome Italy
| | - S. Oppi
- Hematology; Businco Oncology Hospital; Cagliari Italy
| | - S. Viviani
- Hematology; National Institute of tumors; Milan Italy
| | - S. Bolis
- Hematology; S. Gerardo University Hospital; Monza Italy
| | | | - G. Gini
- Hematology; Ospedali Riuniti Le Torrette; Ancona Italy
| | - R. Battistini
- Hematology; S. Camillo Forlanini Hospital; Rome Italy
| | - S. Chauvie
- Medical Physics; S. Croce Hospital; Cuneo Italy
| | | | - C. Pavoni
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - G. Parvis
- Hematology; Mauriziano Hospital; Turin Italy
| | - R. Zanotti
- Hematology; Azienda Ospedaliera Universitaria Integrata; Verona Italy
| | - P. Gavarotti
- Hematology; University Hospital Città della salute; Turin Italy
| | | | | | - P. Viero
- Hematology; Dell'Angelo Hospital; Venice Italy
| | - A. Avigdor
- Hematolog and Bone Marrow Transplantation; Sheba Medical Center; Tel-Aviv Israel
| | - C. Tarella
- Hematology; European Institute of Oncology; Milan Italy
| | - A. Rambaldi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| |
Collapse
|
4
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
5
|
Gallamini A, Schiano de Colella J, Viotti J, Bijou F, Rambaldi A, Perrot A, Patti C, Gastaud L, Sorasio R, Debaigt C, Schiappa R, Chamorey E, Viviani S, Thyss A. BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). Hematol Oncol 2019. [DOI: 10.1002/hon.101_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gallamini
- Clinical Research and Innovation; A. Lacassagne Cancer Center; Nice France
| | | | - J. Viotti
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - F. Bijou
- Oncologie Médicale; Institut Bergonié; Bordeaux France
| | - A. Rambaldi
- Ematologia; Ospedale Papa Giovanni XXII; Bergamo Italy
| | - A. Perrot
- Service Hématologie et Médecine Interne; CHU Nancy-Brabois; Vandoeuvre Les Nancy France
| | - C. Patti
- Ematologia; Ospedali Riuniti Villa Sofia e Cervello; Palermo Italy
| | - L. Gastaud
- Département d'Oncologie Médicale; Centre Antoine Lacassagne; Nice France
| | - R. Sorasio
- Ematologia; Ospedale Sante Croce e Carle; Cuneo Italy
| | - C. Debaigt
- Clinical Research and Innovation; A. Lacassagne Cancer Center; Nice France
| | - R. Schiappa
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - E. Chamorey
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - S. Viviani
- Dipartimento di Oncologia Medica; Istituto Nazionale Dei Tumori; Milano Italy
| | - A. Thyss
- Département d'Oncologie Médicale; Centre Antoine Lacassagne; Nice France
| |
Collapse
|
6
|
Guerra L, Bergesio F, Versari A, Franceschetto A, Peano S, Fallanca F, Storto G, Luminari S, Rigacci L, Gallamini A, Federico M, Chauvie S. INTERIM ANALYSIS OF CENTRAL REVIEW OF END-OF-THERAPY PET IN FOLL12 TRIAL FOR FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.62_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Guerra
- Nuclear Medicine; San Gerardo Hospital - ASST Monza; Monza Italy
| | - F. Bergesio
- Medical Physics; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - A. Versari
- Nuclear Medicine; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - A. Franceschetto
- Nuclear Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - S. Peano
- Nuclear Medicine; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - F. Fallanca
- Nuclear Medicine; San Raffaele Scientific Institute; Milano Italy
| | - G. Storto
- Nuclear Medicine; IRCCS-CROB Referral Cancer Center of Basilicata; Rionero in Vulture Italy
| | - S. Luminari
- Department of Diagnostic Medicine; Clinical and Public Health, University of Modena and Reggio Emilia; Modena Italy
| | - L. Rigacci
- Haematology and Stem Cells Transplantation Unit; San Camillo Forlanini Hospital; Roma Italy
| | - A. Gallamini
- Research and Clinical Innovation; Antoine Lacassagne Cancer Center; Nice France
| | - M. Federico
- CHIMOMO; University of Modena and Reggio Emilia; Modena Italy
| | - S. Chauvie
- Medical Physics; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| |
Collapse
|
7
|
Mazza R, Spina M, Califano C, Gaudio F, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati A, Rodari M, Giordano L, Balzarotti M, Gallamini A, Ricardi U, Chauvie S, Merli F, Carlo-Stella C, Santoro A. DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.100_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Mazza
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - M. Spina
- Medical Oncology Division; Centro Riferimento Oncologico; Aviano Italy
| | - C. Califano
- Onco-Hematology Department; A. Tortora Hospital; Pagani Italy
| | - F. Gaudio
- Emergency and Transplantation Department; Hematology section, University of Bari; Bari Italy
| | - M. Carella
- Hematological Consultant; Casa di Cura La Madonnina; Milano Italy
| | - U. Consoli
- Garibaldi Nesima Hospital; Hematology Department; Catania Italy
| | - F. Palombi
- Hematology Department; Regina Elena National Cancer Institute; Roma Italy
| | - M. Musso
- Onco-Hematology Unit; Casa di Cura “La Maddalena”; Palermo Italy
| | - A. Pulsoni
- Cellular Biotechnologies and Hematology Department; Policlinico Umberto I, Sapienza University; Rome Italy
| | - S. Kovalchuk
- Hematology Department; AOU Carreggi; Firenze Italy
| | - M. Bonfichi
- Hematology Division; IRCCS Policlinico S. Matteo; Pavia Italy
| | - F. Ricci
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - A. Fabbri
- Hematology Unit; AOU Senese; Siena Italy
| | - A. Liberati
- Onco-Hematology Division; S. Maria Hospital; Terni Italy
| | - M. Rodari
- Humanitas Reserch Hospital; Nuclear Medicin Unit; Rozzano-Milano Italy
| | - L. Giordano
- Biostatistic Unit; Humanitas Research Hospital; Rozzano Milano Italy
| | - M. Balzarotti
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - A. Gallamini
- Research; Innovation and Statistc Depatment, Centre Antoine-Lacassagne; Nice France
| | - U. Ricardi
- Oncology Department; Radiation Oncology, University of Torino; Torino Italy
| | - S. Chauvie
- Medical Physics Department; S Croce e Carle Hospital; Cuneo Italy
| | - F. Merli
- Hematology Department; Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - C. Carlo-Stella
- Medical Oncology and Hematology Department; Humanitas University; Rozzano-Milano Italy
| | - A. Santoro
- Medical Oncology and Hematology Department; Humanitas University; Rozzano-Milano Italy
| |
Collapse
|
8
|
Gallamini A. Hodgkin lymphoma staging 50 years later: no more knives or needles! Ann Oncol 2018; 29:1892-1893. [PMID: 30052746 DOI: 10.1093/annonc/mdy262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Gallamini
- Research, Innovation and Statistics Department, Antoine Lacassagne Cancer Center, Nice, France.
| |
Collapse
|
9
|
Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W, Fijolek-Warszewska A, Biggi A, Fallanca F, Kobylecka M, Dziuk M, Woszczyk D, Rybka J, Kroll-Balcerzak R, Bergesio F, Romanowicz A, Chamier-Cieminska A, Kurczab P, Giza A, Lesniewski-Kmak K, Zaucha R, Swietlik D, Wróbel T, Knopinska-Posluszny W, Walewski J, Gallamini A. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Ann Oncol 2018; 28:3051-3057. [PMID: 28950332 DOI: 10.1093/annonc/mdx524] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin's lymphoma. To test whether an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value of iPET after one ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning. Patients and methods Consecutive patients with newly diagnosed classical Hodgkin's lymphoma underwent interim PET scan after one ABVD course (iPET1). PETs were interpreted according to the Deauville score (DS) as negative (-) (DS 1-3) and positive (+) (DS 4, 5). Patients with iPET1 DS 3-5 underwent iPET2. Results About 106 early (I-IIA) and 204 advanced (IIB-IV) patients were enrolled between January 2008 and October 2014. iPET1 was (-) in 87/106 (82%) or (+) in 19/106 (18%) of early, and (-) in 133/204 (65%) or (+) in 71/204 (35%) of advanced stage patients, respectively. Twenty-four patients were excluded from response analysis due to treatment escalation. After a median follow-up of 38.2 (3.2-90.2) months, 9/102 (9%) early and 43/184 (23%) advanced patients experienced a progression-free survival event. At 36 months, negative and positive predictive value for iPET1 were 94% and 41% (early) and 84% and 43% (advanced), respectively. The kinetics of PET response was assessed in 198 patients with both iPETs. All 116 patients with iPET1(-) remained iPET2(-) (fast responders), 41/82 with IPET1(+) became iPET2(-) (slow responders), and the remaining 41 stayed iPET2(+) (non-responders); progression-free survival at 36 months for fast, slow and non-responders was 0.88, 0.79 and 0.34, respectively. Conclusion The optimal tool to predict ABVD outcome in HL remains iPET2 because it distinguishes responders, whatever their time to response, from non-responders. However, iPET1 identified fast responders with the best outcome and might guide early treatment de-escalation in both early and advanced-stage HL.
Collapse
Affiliation(s)
- J M Zaucha
- Gdynia Oncology Center, Gdynia.,Departments of Oncological Propedeutics.,Hematology and Transplantology, Medical University of Gdańsk, Gdańsk
| | - B Malkowski
- Nuclear Medicine Department, Oncology Center, Bydgoszcz.,Positron Emission Tomography and Molecular Imagining Department, Collegium Medicum N. Copernicus University, Bydgoszcz, Poland
| | - S Chauvie
- Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy
| | - E Subocz
- Department of Hematology, Military Institute of Medicine, Warszawa
| | - J Tajer
- Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa
| | - W Kulikowski
- Clinical Department of Hematology, Interior Ministry Hospital, Warmia.,Mazury Medical University, Olsztyn
| | | | - A Biggi
- Nuclear Medicine Department, Santa Croce e Carle Hospital, Cuneo
| | - F Fallanca
- Nuclear Medicine Department, San Raffaele Hospital, Milano, Italy
| | - M Kobylecka
- Nuclear Medicine Department, Warsaw Medical University, Warszawa
| | - M Dziuk
- Nuclear Medicine Department, Military Institute of Medicine, Warszawa
| | - D Woszczyk
- Hematology Unit, Regional Hospital, Opole
| | - J Rybka
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw
| | | | - F Bergesio
- Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy
| | - A Romanowicz
- Department of Hematology, Central Clinical Hospital MSW, Warszawa
| | | | - P Kurczab
- Poradnia Onkologiczna z Oddzialem Chemioterapii Dziennej NZOZ Mrukmed, Rzeszów
| | - A Giza
- Department of Hematology, Jagiellonian University Medical College, Krakow
| | - K Lesniewski-Kmak
- Gdynia Oncology Center, Gdynia.,Departments of Oncological Propedeutics.,Hematology and Transplantology, Medical University of Gdańsk, Gdańsk
| | - R Zaucha
- Department of Clinical Oncology and Radiotherapy
| | - D Swietlik
- Intrafaculty College of Medical Informatics & Biostatistics, Medical University of Gdansk, Poland
| | - T Wróbel
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw
| | - W Knopinska-Posluszny
- Clinical Department of Hematology, Interior Ministry Hospital, Warmia.,Mazury Medical University, Olsztyn
| | - J Walewski
- Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa
| | - A Gallamini
- Department of Research, Innovation and Statistics, A. Lacassagne Cancer Center, Nice, France
| |
Collapse
|
10
|
Gallamini A, Meignan M. PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question. Eur J Nucl Med Mol Imaging 2017; 45:1-3. [PMID: 29026947 DOI: 10.1007/s00259-017-3841-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 09/24/2017] [Indexed: 10/18/2022]
Affiliation(s)
- A Gallamini
- Research, innovation and statistics department, Lacassagne Cancer Center, 33 Rue de Valombrose, 06129, Nice, France.
| | - M Meignan
- LYSA imaging center, Hôpital Henri Mondor, Creteil, France
| |
Collapse
|
11
|
Gallamini A, Bijou F, Viotti J, Rossi A, Perrot A, Patti C, Gastaud L, Sorasio R, Debaigt C, Chamorey E, Viviani S, Thyss A. BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_28] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Gallamini
- Research Innovation and statistics; Antoine Lacassagne Cancer Center; Nice France
| | - F. Bijou
- Hematologie; Institut Bergonié; Bordeaux France
| | - J. Viotti
- Unité de Epidemiologie et Biostatistique; Antoine Lacassagne Cancer Center; Nice France
| | - A. Rossi
- Hematology; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - A. Perrot
- Hematologie; CHU Nancy-Brabois; Nancy France
| | - C. Patti
- Ematologia; Ospedale V. Cervello e Villa Sofia; Palermo Italy
| | - L. Gastaud
- Hematologie Oncolologie; Antoine Lacassagne Cancer Center; Nice France
| | - R. Sorasio
- Ematologia; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - C. Debaigt
- Research Innovation and statistics; Antoine Lacassagne Cancer Center; Nice France
| | - E. Chamorey
- Unité de Epidemiologie et Biostatistique; Antoine Lacassagne Cancer Center; Nice France
| | - S. Viviani
- Ematologia e trapianto MO; Istituto Nazionale Tumori; Milan Italy
| | - A. Thyss
- Hematologie Oncolologie; Antoine Lacassagne Cancer Center; Nice France
| |
Collapse
|
12
|
Zaucha J, Khair W, Biecek P, Subocz E, Tajer J, Kulikowski W, Panebianco M, Grad J, Rybka J, Kroll-Balcerzak R, Romanowicz A, Chmielowska E, Kurczab P, Malkowski B, Juszczynski P, Cimino G, Walewski J, El-Galaly T, Gallamini A, Dann E. Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J.M. Zaucha
- Gdynia Oncology Center, Gdynia and Department of Oncological Propedeutics; Medical University of Gdansk; Gdynia Poland
| | - W. Khair
- Department of Hematology Aalborg University Hospital and Department of Clinical Medicine; Aalborg University; Aalborg Denmark
| | - P. Biecek
- Faculty of Mathematics and Information Science; Warsaw University of Technology; Warszawa Poland
| | - E. Subocz
- Department of Hematology; Military Institute of Medicine; Warszawa Poland
| | - J. Tajer
- Department of Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - W. Kulikowski
- Clinical Department of Oncology, Interior Ministry Hospital; Warmia and Mazury Medical University; Olsztyn Poland
| | - M. Panebianco
- Department of Cellular Biotechnology and Hematology; University "La Sapienza" of Rome; Rome Italy
| | - J. Grad
- Hematology Unit, Regional Hospital; Opole Poland
| | - J. Rybka
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation; Wroclaw Medical University; Wroclaw Poland
| | | | - A. Romanowicz
- Department of Hematology; Central Clinical Hospital MSW; Warszawa Poland
| | - E. Chmielowska
- Department of Clinical Oncology; Oncology Center; Bydgoszcz Poland
| | - P. Kurczab
- Outpatient Chemotherapy Unit; Medical Center Mrukmed; Rzeszow Poland
| | - B. Malkowski
- Nuclear Medicine Department; Oncology Center; Bydgoszcz Poland
| | - P. Juszczynski
- Department of Experimental Hematology; Institute of Hematology and Transfusion Medicine; Warszawa Poland
| | - G. Cimino
- Department of Cellular Biotechnology and Hematology; University "La Sapienza" of Rome; Rome Italy
| | - J. Walewski
- Department of Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - T.C. El-Galaly
- Department of Hematology Aalborg University Hospital and Department of Clinical Medicine; Aalborg University; Aalborg Denmark
| | - A. Gallamini
- Research, Innovation and statistics department, Lacassagne Cancer Center; Nice University; Nice France
| | - E.J. Dann
- Rambam Health Care Campus, Haifa and Rappaport Faculty of Medicine, Technion; Haifa Israel
| |
Collapse
|
13
|
Gallamini A, Borra A, Zwarthoed C. PET response-adapted clinical trials in Hodgkin lymphoma: a comprehensive review. Clin Transl Imaging 2015. [DOI: 10.1007/s40336-015-0124-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Gallamini A, Kostakoglu L. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma? Ann Oncol 2015; 26:1045-1047. [PMID: 26003616 DOI: 10.1093/annonc/mdv160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Gallamini
- Department of Research, Innovation and Statistics, A. Lacassagne Cancer Centre, Nice, France.
| | - L Kostakoglu
- Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, USA
| |
Collapse
|
15
|
Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia 2015; 29:1360-5. [DOI: 10.1038/leu.2015.21] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/25/2014] [Accepted: 12/10/2014] [Indexed: 11/09/2022]
|
16
|
Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, Pimpinelli N, Rossi G, Zinzani P, Tura S. SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol 2014; 25:2339-2350. [DOI: 10.1093/annonc/mdu152] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
17
|
Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri A, Zinzani P, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo F, Carella A, Micol Q, Balzarotti M, Musto P, Federico M. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2014; 25:442-7. [DOI: 10.1093/annonc/mdt562] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, Spina M, Ferreri A, Zinzani P, Gallamini A, Mastronardi S, Boccomini C, Gaidano G, D'Arco A, Di Raimondo F, Carella A, Santoro A, Musto P, Federico M. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013; 24:2108-12. [DOI: 10.1093/annonc/mdt137] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
19
|
Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24:857-77. [PMID: 23425945 DOI: 10.1093/annonc/mds643] [Citation(s) in RCA: 223] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma. The conference convened ∼30 experts from all around Europe, and selected six lymphoma entities to be addressed; for each of them, three to five open questions were to be addressed by the experts. For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.
Collapse
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital, LMU Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Zaucha J, Malkowski B, Gallamini A. PR52 The value of dual point interim FDG-PET/CT assessment in a patient with advanced Hodgkin's lymphoma (HL) with bulky masses treated with ABVD chemotherapy. Crit Rev Oncol Hematol 2012. [DOI: 10.1016/s1040-8428(12)70064-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
21
|
Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG–PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 2011; 22:671-680. [DOI: 10.1093/annonc/mdq403] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Fiore F, Patti K, Viviani S, Rossi A, Di Raimondo F, Cantonetti M, Feldman T, Biggi A, Barrington S, Gallamini A. Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Gallamini A, Biggi A, Chauvie S, Bianchi A, Conti S, Fiore F, Sorasio R, Vose J, Thomas DL, Juweid ME. Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64:1274-81. [DOI: 10.1093/jac/dkp355] [Citation(s) in RCA: 114] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, Fabbri A, Battista R, Cabras MG, Gallamini A, Fanin R. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2009; 47:2174-80. [PMID: 17071492 DOI: 10.1080/10428190600799946] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Thirty untreated patients, median age 69 years (range 60 - 75 years), with diffuse large B-cell lymphoma (B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen. PL-doxorubicin 30 mg/m2, was given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses. Cardiac toxicity was evaluated by mean of echocardiography for left ventricular ejection fraction (LVEF) evaluations and serum troponin-I levels. Overall response and complete response rates were 76% and 59%. Projected two year event free survival and overall survival are 65.5% and 68.5%. No treatment-related mortality was documented. WHO grade III-IV neutropenia and thrombocytopenia were 86% and 3%. Extra-hematological III-IV toxicity was represented, respectively, by a single case of infection, mucositis, and bleeding. LVEF evaluations and the troponin levels did not show significant changes over the course of the treatment. One patient with a previous history of atrial fibrillation experienced a single episode of arrhythmia. None of the patients developed palmar-plantar erythrodysesthesia. This regimen appears an active regimen for the treatment of elderly patients with B-DLCL. The replacement of conventional doxorubicin with PL-doxorubicin seems to be associated with a negligible incidence of extra-hematological toxicity, in particular cardiac and infectious complications.
Collapse
Affiliation(s)
- F Zaja
- Division of Hematology, DIRM, University Hospital, Udine, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2008; 43:967-8. [PMID: 19104491 DOI: 10.1038/bmt.2008.415] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
27
|
Zappia E, Musso M, Orsini S, Ribero S, Ungari S, Bertone F, Davit A, Gallamini A, Mattei D, Bracco G. UTILIZZO DELLA REAL TIME PCR PER LA DIAGNOSI DI ASPERGILLOSI IN PAZIENTI IMMUNOCOMPROMESSI. Microbiol Med 2007. [DOI: 10.4081/mm.2007.2859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
28
|
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21:1802-11. [PMID: 17554382 DOI: 10.1038/sj.leu.2404781] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged <65 years (74 score 2, 38 score 3) entered the study protocol. There were five early and two late toxic deaths. Overall 90 patients (80%) reached clinical remission (CR); at a median 48 months follow-up, 87 (78%) patients are alive, 82 (73%) in continuous CR, with 4 year overall survival (OS) and event-free survival (EFS) projections of 76% (CI 68-85%) and 73% (CI 64-81%), respectively. There were no significant differences in OS and EFS between subgroups with Germinal-Center and Activated B-cell phenotype. Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.
Collapse
Affiliation(s)
- C Tarella
- Dip Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Mattei D, Bassan R, Mordini N, Rapezzi D, Rambaldi A, Strola G, Peretti C, Del Grosso F, Ferraris AM, Castellino C, Gallamini A. Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient. Bone Marrow Transplant 2007; 40:283-5. [PMID: 17529999 DOI: 10.1038/sj.bmt.1705714] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
MESH Headings
- Adult
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antigens, CD/genetics
- Antigens, CD/immunology
- Cell Proliferation
- Chromosomes, Human, X/genetics
- Chromosomes, Human, X/immunology
- Cord Blood Stem Cell Transplantation
- Cyclosporine/administration & dosage
- Cyclosporine/adverse effects
- Diarrhea/drug therapy
- Diarrhea/etiology
- Diarrhea/genetics
- Diarrhea/immunology
- Fatal Outcome
- Female
- Gastrointestinal Agents/administration & dosage
- Gastrointestinal Agents/adverse effects
- Graft Survival/immunology
- Graft vs Host Disease/genetics
- Graft vs Host Disease/immunology
- Graft vs Host Disease/pathology
- Graft vs Host Disease/prevention & control
- Humans
- Ileus/drug therapy
- Ileus/etiology
- Ileus/genetics
- Ileus/immunology
- Immunosuppressive Agents/administration & dosage
- Immunosuppressive Agents/adverse effects
- Infliximab
- Leukemia-Lymphoma, Adult T-Cell/complications
- Leukemia-Lymphoma, Adult T-Cell/genetics
- Leukemia-Lymphoma, Adult T-Cell/immunology
- Leukemia-Lymphoma, Adult T-Cell/pathology
- Neoplasm, Residual
- Precursor Cells, B-Lymphoid/immunology
- Precursor Cells, B-Lymphoid/pathology
- Transplantation Chimera/genetics
- Transplantation Chimera/immunology
- Transplantation Conditioning
Collapse
|
30
|
Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni A, Tarella C. P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70080-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Milani R, Zanni M, Dodero A, Spina F, Testi A, Tarella C, Bernardi M, Gallamini A, Bandini G, Benedetti F, Gianni A, Corradini P. P158 Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70228-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Salvi F, Gioia D, Cilloni D, Audisio E, Boccomini C, Bonferroni M, Cametti G, Ciravegna G, Darbesio A, Dellacasa C, Ferrero D, Freilone R, Lunghi M, Gallamini A, Gaidano G, Girotto M, Marmont F, Tonso A, Saglio G, Levis A. P104 Prognostic role of transfusion requirement in myelodysplastic syndromes. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70174-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Gioia D, Cilloni D, Salvi F, Audisio E, Boccomini C, Bonferroni M, Cametti G, Ciravegna G, Darbesio A, Dellacasa C, Ferrero D, Freilone R, Gatto S, Lunghi M, Gallamini A, Gaidano G, Girotto M, Marmont F, Marinone C, Messa E, Perticone S, Pollio B, Tonso A, Saglio G, Levis A. P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70072-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007; 21:697-705. [PMID: 17301820 DOI: 10.1038/sj.leu.2404544] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Some evidences suggest that telomere restriction fragment length (TRF-L) is an effective indicator of histopathogenesis in B-cell tumors. As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features. Overall survival (OS), time to first treatment (TTFT) and progression-free survival (PFS) were evaluated. Our results indicate the following: (1) TRF-L is heterogeneous among B-CLL patients (median 6014 bp, range 1465-16 762); (2) TRF-L correlates to VH-MS (r(2)=0.1994, P<0.0001) with VH-mutated patients showing long and VH-unmutated short telomeres; however, 41% of VH-unmutated and 5% of VH-mutated patients did not show this correlation and were thus defined as 'discordant'; (3) TRF-L effectively predicts outcome in terms of TTFT, PFS and OS; (4) VH-unmutated discordant patients have a better clinical outcome than VH-unmutated concordant patients (OS P<0.01, PFS P<0.05) and similar to that of VH-mutated patients (OS, PFS P=NS). Compared to VH-unmutated concordant patients, VH-unmutated discordant patients showed no peculiarity in their immunoglobulin rearrangement nor in their flow cytometry or fluorescence in situ hybridization profile. In conclusion, TRF-L can be helpful to refine prognostication of B-CLL patients, particularly those with a VH-unmutated immunoglobulin sequence.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Allelic Imbalance
- Burkitt Lymphoma/genetics
- Burkitt Lymphoma/immunology
- Burkitt Lymphoma/mortality
- Disease-Free Survival
- Humans
- Immunoglobulin Variable Region
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Middle Aged
- Neoplasm Staging
- Prognosis
- Survival Analysis
- Telomere/ultrastructure
Collapse
Affiliation(s)
- I Ricca
- Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale--Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol 2006; 17:794-800. [PMID: 16497823 DOI: 10.1093/annonc/mdl015] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients. PATIENTS Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions. RESULTS All patients were Caucasian, male/female ratio was 19/7, with a median age of 50 years (range 20-80). In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement. Regarding the stage of disease: 12 patients were in stage I; six in stage II; eight in stage IV. Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions. All patients but one were treated with chemotherapy, alone in nine cases or associated to radiotherapy in 14 cases; two patients had chemotherapy, radiotherapy and surgery, while one patient underwent only surgery. Chemotherapy was anthracycline-based in 17 out of 25 cases. In those patients in whom radiotherapy was performed, radiation dosages ranged between 36 Gy and 47.5 Gy, with a median dosage of 40 Gy. Nine patients (34%) were responsive to the treatments: six patients obtained a complete remission and other three a partial remission. The remaining 17 patients resulted refractory or presented a limited response to therapy. The median disease-free survival was 14 months and the median overall survival time was 9 months. CONCLUSION The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis. Due to the rarity of this disease, a standardized therapeutic approach is lacking. More data are needed to know the epidemiology of this kind of lymphoma in Europe.
Collapse
Affiliation(s)
- L Pagano
- Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Zaja F, Tomadini V, Zaccaria A, Lauria F, Molinari AL, Fabbri A, Battista R, Angelucci E, Gallamini A, Battista M, Fanin R. Liposomal doxorubicin-liposomal doxorubicin-rituximab for the treatment of elderly patients with diffuse large B-cell lymphoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Zaja
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - V. Tomadini
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - A. Zaccaria
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - F. Lauria
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - A. L. Molinari
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - A. Fabbri
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - R. Battista
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - E. Angelucci
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - A. Gallamini
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - M. Battista
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| | - R. Fanin
- Div of Hematology, Policlinico Univ, Udine, Italy; Div of Hematology, Ravenna, Italy; Div of Hematology, Siena, Italy; Div of Hematology, Chioggia, Italy; Div of Hematology, Cagliari, Italy; Div of Hematology, Cuneo, Italy
| |
Collapse
|
37
|
Salvi F, Godio L, Campa E, Ciriello M, Ferrero D, Gallamini A, Marmont F, Paparo C, Stacchini A, Saglio G, Levis A. P-34 Different modalities of bonemarrow blast quantification can influence diagnostic and prognostic evaluation of myelodysplastic syndromes (MDS). Leuk Res 2005. [DOI: 10.1016/s0145-2126(05)80098-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Steffenino G, Margarial E, Gallamini A, Nigro C, Feola M, Biggil A, Meinardi F, Uslenghil E, Gentile F. Recovery of regional contractile and metabolic function after autologous bone marrow stem cell implantation: a randomised study. Int J Cardiol 2004. [DOI: 10.1016/s0167-5273(04)90021-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90:372-6. [PMID: 14735179 PMCID: PMC2409547 DOI: 10.1038/sj.bjc.6601460] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B (95). The two groups of patients were similar as regard to age, gender, presence of bulky mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk. Overall, 75.5% of patients in CR received IF-RT as consolidation. Complete remission was 51.1% in the CHOP group and 80% in MACOP-B/VACOP-B (P<0.001). Relapse occurred in 22.7% of CHOP- and in 9.2% of MACOP-B/VACOP-B-treated patients (n.s.). Event-free patients were 39.5% in CHOP and 75.7% in the MACOP-B/VACOP-B group (P<0.001). The addition of IF-RT as consolidation improved the outcome, irrespectively of the type of chemotherapy (P=0.04). At a multivariate analysis, achievement of CR (P<0.0001) and type of CT (MACOP-B/VACOP-B) retained the significance for OS (P=0.008) and EFS (P=0.03). In our experience, MACOP-B/VACOP-B appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on mediastinum further improves the outcome of CR patients.
Collapse
Affiliation(s)
- G Todeschini
- Department of Hematology, Verona University, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We report two cases of Acremonium fungemia with proven involvement of the skin and probably of the lung in patients who were both undergoing chemotherapy, one for mantle cell lymphoma and the other for acute lymphoblastic leukemia. Both patients failed amphotericin B deoxycholate treatment and were successfully treated with voriconazole with very mild toxicity.
Collapse
Affiliation(s)
- D Mattei
- Department of Hematology, S. Croce Hospital, Cuneo, Italy.
| | | | | | | | | | | | | |
Collapse
|
41
|
Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30:725-32. [PMID: 12439694 DOI: 10.1038/sj.bmt.1703729] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2002] [Accepted: 07/15/2002] [Indexed: 11/08/2022]
Abstract
A high-dose (HD) chemotherapy scheme was designed for the collection of large numbers of peripheral blood progenitor cells (PBPC) in lymphoma patients who were candidates for myeloablative therapy with autograft. The scheme included the sequential administration of HD cyclophosphamide (CY) (7 g/m(2)) and HD ara-C (2 g/m(2) twice a day for 6 consecutive days), followed by final consolidation with PBPC autograft. PBPC harvests were scheduled following both HD CY and HD ara-C. To minimize hematologic toxicity, small aliquots of PBPC (<or=3 x 10(6) CD34(+) cells/kg) collected following HD CY were reinfused following HD ara-C. The treatment was delivered to 112 patients (median age: 43 years) with lymphoid malignancies (107 non-Hodgkin's lymphoma, four Hodgkin's lymphoma, one amyloidosis); 75 patients were at disease onset, whereas 37 had relapsed or were refractory after first-line conventional therapy. PBPC mobilization was assessed in terms of peak values of circulating CD34(+) cells/microl, as well as total CD34(+) cells/kg collected. In a few patients CFU-GM/kg were also evaluated. At the time of maximal mobilization following HD CY, 93 'high-mobilizer' patients had >20 circulating CD34(+) cells/microl, whereas the remaining 19 'low-mobilizer' patients did not reach this cut-off value. In spite of poor mobilization after HD CY, 16 out of 19 low mobilizers provided good harvests following HD ara-C; overall, median collected CD34(+) cells x 10(6)/kg were 1.4 (0-3.1) and 10.2 (0-37) after HD CY and HD ara-C, respectively (P = 0.00007). Similar patterns were observed when PBPC were evaluated by CFU-GM/kg. Complete and durable hemopoietic reconstitution followed autograft with post HD ara-C PBPC. Within the high-mobilizer group, 88 patients received HD ara-C and 79 (90%) still showed high mobilization; overall, median collected CD34(+)cells x 10(6)/kg were 17.8 (range 3-94) and 19 (range 0-107) after HD CY and HD ara-C respectively (P = NS). Thus, the scheme allowed sufficient PBPC collections for autografting in low mobilizer patients; in addition, the scheme could be considered whenever extensive chemotherapy debulking is needed prior to PBPC collection.
Collapse
Affiliation(s)
- C Tarella
- Dip Med Oncol Sperimentale, Div Univ Ematologia, AO S Giovanni B, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Mattei D, Mordini N, Lo Nigro C, Ghirardo D, Ferrua MT, Osenda M, Gallamini A, Bacigalupo A, Viscoli C. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant 2002; 30:967-70. [PMID: 12476292 DOI: 10.1038/sj.bmt.1703763] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2002] [Accepted: 08/10/2002] [Indexed: 11/09/2022]
Abstract
The management of invasive aspergillosis in patients with hematological malignancies remains controversial. A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT. Indeed in these patients the mortality rate related to invasive aspergillosis recurrence remains unacceptably high. We report two cases of patients who underwent remission induction for AML, developed invasive aspergillosis during antifungal prophylaxis with itraconazole, failed amphotericin B deoxycholate and liposomal amphotericin B treatment, were successfully treated with voriconazole and eventually underwent SCT with voriconazole prophylaxis without reactivation of invasive aspergillosis.
Collapse
MESH Headings
- Adult
- Amphotericin B/administration & dosage
- Amphotericin B/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Aspergillosis/drug therapy
- Aspergillosis/etiology
- Aspergillosis/prevention & control
- Bone Marrow Transplantation/adverse effects
- Combined Modality Therapy
- Cytarabine/administration & dosage
- Cytarabine/adverse effects
- Daunorubicin/administration & dosage
- Daunorubicin/adverse effects
- Deoxycholic Acid/administration & dosage
- Deoxycholic Acid/analogs & derivatives
- Deoxycholic Acid/therapeutic use
- Drug Combinations
- Drug Resistance, Fungal
- Etoposide/administration & dosage
- Etoposide/adverse effects
- Fatal Outcome
- Humans
- Immunocompromised Host
- Itraconazole/therapeutic use
- Leukemia, Megakaryoblastic, Acute/complications
- Leukemia, Megakaryoblastic, Acute/drug therapy
- Leukemia, Megakaryoblastic, Acute/therapy
- Leukemia, Myelomonocytic, Acute/complications
- Leukemia, Myelomonocytic, Acute/drug therapy
- Leukemia, Myelomonocytic, Acute/therapy
- Liposomes
- Lung Diseases, Fungal/drug therapy
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation/adverse effects
- Pyrimidines/therapeutic use
- Recurrence
- Remission Induction
- Salvage Therapy
- Transplantation Conditioning/adverse effects
- Transplantation, Autologous/adverse effects
- Transplantation, Homologous/adverse effects
- Triazoles/therapeutic use
- Voriconazole
Collapse
Affiliation(s)
- D Mattei
- Hematology Department, S Croce Hospital, Cuneo, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Mattei D, Saglio G, Gottardi E, Gallamini A, Mordini N, Bacigalupo A. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 2001; 86:545-6. [PMID: 11410423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
|
44
|
Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM, Truini M, Rubagotti A, Chisesi T, Vimercati R, Rossi E, Sertoli MR, Mattei D, Marino G, Gobbi M. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86:282-6. [PMID: 11255275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
BACKGROUND AND OBJECTIVES We report the activity of two combinations of fludarabine (FLU), one with cyclophosphamide (FLU/CY) and the second with CY plus mitoxantrone (FLU/CY/MITO). The aim of the study was to evaluate the activity and toxicity of these two schedules in patients with non-Hodgkin's lymphoma (NHL). DESIGN AND METHODS Twenty-two patients with recurrent low grade non-Hodgkin's lymphoma (LGL) received FLU/CY (FLU 25 mg/m(2) days 1 to 3, CY 300 mg/m(2) days 1 to 3), and 31 patients received FLU/CY/MITO (FLU 25 mg/m(2) days 1 to 3, CY 300 mg/m(2) days 1 to 3, mitoxantrone 10 mg/m(2) day 1). Patients received antibiotic oral prophylaxis during all treatments and growth factors (G-CSF) when grade III granulocytopenia (WHO scale) occurred. RESULTS Of the 53 patients, 31 achieved complete remission (CR) (58%) and 16 partial remission (PR) (30%). Response was similar in both arms of the study. After 3 courses, 77% of patients who achieved CR showed a complete disappearance of disease. Seventy-nine per cent of patients experienced granulocytopenia. Few patients had fever, all without infection. One patient died with fever of unknown origin three months after completion of six courses of treatment. INTERPRETATION AND CONCLUSIONS Both treatments were seen to be effective in recurrent low-grade NHL. Antibiotic prophylaxis with G-CSF support seems to reduce treatment-related infection.
Collapse
Affiliation(s)
- G Santini
- Divisione di Ematologia, Azienda Ospedaliera S. Martino, Ospedale S. Martino, largo Rosanna Benzi 10, 16132 Genoa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Gallamini A, Biggi A, Fruttero A, Pugno F, Cavallero G, Pregno P, Grasso M, Farinelli C, Leone A, Gallo E. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1997; 24:1499-506. [PMID: 9391185 DOI: 10.1007/s002590050180] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The purpose of this study was threefold: to evaluate the role of gallium-67 scintigraphy in the staging of low-grade non-Hodgkin's lymphomas (LGNHL), to assess the relationship between the expression of CD71 on the surface of the neoplastic cells and the 67Ga uptake by the tumour, and to establish the contribution of 67Ga scan in defining the prognosis of LGNHL. Forty-eight patients with untreated LGNHL diagnosed in a single institution over a decade were reviewed. The end point of the study was survival of the patients according to the scintigraphic 67Ga score at diagnosis. In addition to 67Ga scan, other prognostic variables were studied, relating to the neoplastic burden, the biology of the tumour and the host. Univariate and multivariate analyses were used. 67Ga scan identified only 116/286 (41%) nodes involved by lymphoma that were detected by clinical examination or computed tomography scan. A scintigraphic scoring system with an arbitrary cut-off value of 3 (high scan score) was able to predict patients with a dismal prognosis: with a mean follow-up of 47 months (range: 1-146 months) the median survival time was 28 months in patients with a high scan score and 74 months in patients with a low scan score (P=0.002). CD71 values were 27. 4%+/-14.9% (mean +/-SD) in the former and 8.9%+/-7.2% in the latter (P=0.0001). Only performance status and extranodal sites were significant variables for prognosis in multivariate analysis. It is concluded that 67Ga scan is inaccurate in staging but might be very important in defining the prognosis in LGNHL, in association with other prognostic variables.
Collapse
Affiliation(s)
- A Gallamini
- Division of Haematology, S. Croce Hospital, Cuneo, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Rota Scalabrini D, Salvi F, Todeschini G, Vitolo U, Resegotti L. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica 1997; 82:309-13. [PMID: 9234577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Idarubicin is an effective drug in acute leukemia but its use in non-Hodgkin lymphomas (NHLs) is not yet well established. We evaluated its efficacy in patients with diffuse large cell lymphoma (DLCL) by means of a randomized trial comparing two 12-week regimens (VACOP-B and VICOP-B) which differed only in the anthracycline drug used (doxorubicin vs idarubicin). METHODS From January 1992 to December 1994, 104 patients aged less than 65 years with de novo advanced stage DLCL were enrolled. Fifty-two patients were treated with VACOP-B (doxorubicin 50 mg/sqm) and 52 with VICOP-B (idarubicin initially 8 mg/sqm and thereafter 10 mg/sqm). RESULTS Clinical characteristics of the two groups were not significantly different. One HBsAg+ patient died of hepatic necrosis in the VICOP-B arm, and severe (WHO grade > 2) toxicities occurred in 7 patients treated with VACOP-B and in 5 treated with VICOP-B; the only significant difference was for mucositis (p = 0.02). Complete remission (CR) was obtained in 79% of patients receiving VACOP-B and in 56% (idarubicin 8 mg/sqm) and 75% (idarubicin 10 mg/sqm) of those in the VICOP-B group (p = n.s.). Prognostic factors that negatively affected CR were advanced stage in VACOP, bone marrow infiltration in both schedules. At a median follow-up of two years, overall survival (67% VACOP and 61% VICOP) and disease-free survival (65% and 67%, respectively) were not significantly different. INTERPRETATION AND CONCLUSIONS Idarubicin is slightly less toxic than doxorubicin; at a dose of 10 mg/sqm the former is easily tolerated and shows the same efficacy as doxorubicin in the treatment of DLCL.
Collapse
Affiliation(s)
- M Bertini
- Divisione di Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Freilone R, Botto B, Vitolo U, Bertini M, Audisio E, Calvi R, Cucchi M, De Crescenzo A, Gallamini A, Ghio R, Griso L, Levis A, Massara G, Orsucci L, Ricardi U, Rota Scalabrini D, Salvi F, Secondo V, Resegotti L. Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma. Ann Oncol 1996; 7:919-24. [PMID: 9006742 DOI: 10.1093/oxfordjournals.annonc.a010794] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND A cooperative study was undertaken to evaluate the efficacy and toxicity of a very brief course of chemotherapy followed by locoregional radiotherapy in patients with localized-stage intermediate- to high-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHOD From January 1988 to November 1994, 84 patients with localized stages IA and IIA intermediate- to high-grade NHL underwent a combined modality treatment. All patients underwent a six-week chemotherapy regimen, ACOP-B (doxorubicin 50 mg/sqm and cyclophosphamide 350 mg/sqm on weeks 1, 3, 5; vincristine 1.4 mg/sqm and bleomycin 10 mg/sqm on weeks 2, 4, 6; prednisone 50 mg p.o. daily throughout the first two weeks and thereafter every other day), followed by locoregional radiotherapy (36 Gy). RESULTS The median age was 58 years, with 35% older than 65 years; 52 patients had stage I and 32 stage II; 39 patients had extranodal +/- nodal involvement, and 4 had testicular involvement. Treatment was well tolerated, with only 38% suffering from mild mucositis and no toxic deaths. Seventy-nine patients achieved CR after ACOP-B and 83 at the end of the program. With a median follow-up of four years, relapse-free survival was 79% with 15 relapses (93% disseminated). Two patients with testis lymphoma had CNS relapses. Overall survival was 90% at four years. CONCLUSION This combined program is effective and probably curative in localized stage intermediate- to high-grade NHL, with low toxicity, also in elderly people. Patients with NHL of the testis, as primary site, require CNS prophylaxis due to the high likelihood of CNS relapse.
Collapse
Affiliation(s)
- R Freilone
- Divisione di Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Levis A, Depaoli L, Bertini M, Botto B, Ciravegna G, Freilone R, Gallamini A, Gavarotti P, Ricardi U, Rota Scalabrini D, Salomone A, Salvi F, Vitolo U, Pileri A, Sannazzari GL, Resegotti L. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81:450-6. [PMID: 8952159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Hodgkin's disease (HD) after the age of 65 years is uncommon and there are no published data on chemotherapy regimens devised for elderly HD patients. PATIENTS AND METHODS From 1990 to 1993, 25 elderly HD patients were treated with the CVP/CEB regimen: chlorambucil 6 mg/sqm p.o. days 1 through 7, vinblastine 6 mg/sqm i.v. on day 1, procarbazine 100 mg/sqm p.o. days 1 through 7, prednisone 30 mg/sqm p.o. days 1 through 7, cyclophosphamide 500 mg./sqm i.v. day 15, etoposide 70 mg/sqm i.v. day 15, bleomycin 10 mg/sqm i.v. day 15. Each course was repeated every 4 weeks. Stage I and II patients were treated with 3 courses followed by involved field radiotherapy, while more advanced stage patients received 6 courses and radiotherapy was limited to bulky areas. The results of the CVP/CEB regimen are retrospectively compared to those of 74 elderly patients treated between 1982 and 1989 and subdivided into the following 2 groups: 32 patients treated according to the same therapy used at that time in younger patients, and 42 patients given alternative low aggressivity or palliative treatment. RESULTS CVP/CEB is a well-tolerated regimen, with only 1 (4%) toxic death and 2 (8%) protocol violations/interruptions. The CVP/CEB complete remission rate (73%) compares favorably with our previous groups of patients, mainly because of the lower toxic death rate. However, the CVP/CEB relapse-free survival rate is lower than that of patients treated with more aggressive conventional regimens (47% vs. 77%, p < 0.02). The CVP/CEB overall survival and event-free survival rates are 55% and 32%, respectively, and they are not statistically different from those of patients treated before 1990. CONCLUSIONS CVP/CEB is a well-tolerated low toxicity regimen with a high CR rate. The relapse rate is high and event-free survival is comparable to that of patients treated conventionally. Our results suggest the need for individualized treatment criteria for older patients with HD.
Collapse
Affiliation(s)
- A Levis
- Department of Hematology, Ospedale SS. Antonio e Biagio, Alessandria, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Gallamini A, Carbone A, Lista P, Cavallero G, Reato G, Fruttero A, Novero D, Asnaghi G, di Celle PF, Foa R. Intestinal T-cell lymphoma with massive tissue and blood eosinophilia mediated by IL-5. Leuk Lymphoma 1995; 17:155-61. [PMID: 7773153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A case of enteropathy associated T-cell lymphoma (EATCL) in a 62-year-old female with a previous history of coeliac disease, complicated during the clinical course by massive blood and tissue eosinophilia is described. The patient's serum contained a factor capable of stimulating the in vitro growth of eosinophilic colonies (CFU-Eo), that was absent in the serum of normal donors. We suggest that such factor was Interleukin-5 (IL-5), as indicated by the presence in the monoclonal tumor T cells of IL-5 encoding mRNA, usually absent in the normal enterocytes of the jejunum.
Collapse
Affiliation(s)
- A Gallamini
- Divisione di Medicina, University of Torino, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini G. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995; 85:1348-53. [PMID: 7532040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Patients with severe aplastic anemia (SAA) and a neutrophil (PMN) count of less than 0.5 x 10(9)/L are exposed to a high risk of early mortality when treated with antilymphocyte globulin (ALG) and steroids, with the major problem being infectious complications. The addition of human recombinant granulocyte colony-stimulating factor (rhG-CSF) to ALG may reduce early mortality by improving neutrophil counts in the short term. To test the feasibility of this approach, the SAA Working Party of the European Group for Blood and Marrow Transplantation (EBMT) designed a pilot study that included rhG-CSF (5 micrograms/kg/d, days 1 through 90), horse ALG (HALG; 15 mg/kg/d, days 1 through 5), methylprednisolone (2 mg/kg/d, days 1 through 5, then tapering the dose), and cyclosporin A (CyA; 5 mg/kg/d orally, days 1 through 180). Patients with newly diagnosed acquired SAA (untreated) and with neutrophil counts of < or = 0.5 x 10(9)/L were eligible. Forty consecutive patients entered this study and are evaluable with a minimum follow up of 120 days: the median age was 16 years (range, 2 to 72 years), the interval from diagnosis to treatment was 24 days, and the median PMN count was 0.19 x 10(9)/L. Twenty-one patients had hemorrhages, and 19 were infected at the time of treatment. Overall, treatment was well tolerated: the median maximum PMN count during rhG-CSF administration was 12 x 10(9)/L (range, 0.4 x 10(9)/L to 44 x 10(9)/L). There were three early deaths (8%) due to infection. Four patients (10%) showed no recovery, whereas 33 patients (82%) had trilineage hematologic reconstitution and became transfusion-independent at a median interval of 115 days from treatment. Median follow up for surviving patients is 428 days (range, 122 to 1,005). Actuarial survival is 92%: 86% and 100% for patients with PMN counts less than 0.2 x 10(9)/L or between 0.2 x 10(9)/L and 0.5 x 10(9)/L, respectively. This study suggests that the addition of rhG-CSF to ALG and CyA is well tolerated, is associated with a low risk of mortality, and offers a good chance of hematologic response. This protocol would appear to be an interesting alternative treatment for SAA patients with a low PMN count who lack an HLA-identical sibling.
Collapse
Affiliation(s)
- A Bacigalupo
- EBMT Working Party on SAA, Ospedale San Martino, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|